Jump to content

Crotedumab

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by AztecWarrior28 (talk | contribs) at 19:54, 7 February 2018 (add UNII). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Crotedumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetGCGR
Clinical data
Other namesREGN1193
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6518H10044N1732O2052S46
Molar mass147.0 kDa g·mol−1

Crotedumab (REGN1193) (INN) is a humanized monoclonal antibody designed for the treatment of diabetes.[1][2]

This drug was developed by Regeneron Pharmaceuticals.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Crotedumab, American Medical Association.
  2. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Crotedumab&oldid=824509837"